On October 25th, the second annual meeting of the DREAMS team was held in Brussels, showcasing the achievements made during the first year. The DREAMS project, known as “Drug Repurposing with Artificial Intelligence for Muscular Disorders,” has been marked by an incredible year filled with significant advancements in foundational research and clinical trial development, laying the groundwork for potential breakthroughs in treatments for five debilitating conditions that affect over 400,000 individuals worldwide.
Notable Achievements and Developments
During this gathering, each of the DREAMS partners presented their progress and how it has laid the groundwork for future innovations. With a pioneering approach, DREAMS combines artificial intelligence, pluripotent stem cell technology, and pharmacological screening methods to explore new treatment possibilities. Since the project’s inception back in November 2023, the project team has made significant strides in creating cellular models for these five neuromuscular diseases. These models are expected to play a crucial role in enhancing our understanding of disease mechanisms in the coming years.
Collaboration with clinicians and patient associations is as well a cornerstone of the DREAMS initiative. In line with this collaborative spirit, the project has successfully identified several European patients impacted by these conditions and established efficient logistics for reprogramming their blood samples into induced pluripotent stem cells (iPS). This groundwork supports the development of a robust methodological framework for upcoming clinical trials, utilizing novel “basket” and “seamless” trial designs that foster close collaboration among a diverse group of clinicians and expert patients.
Moreover, significant advancements in artificial intelligence (AI) have been made, allowing the team to predict drug targets and mechanisms of action more effectively. This state-of-the-art AI research is set to accelerate the identification of promising therapeutic candidates, with multiple scientific publications already in progress to showcase these advancements.
Reflecting on the project’s achievements, Professor Xavier Nissan, Director of Research at I-Stem and Coordinator of DREAMS, stated, “The first year of the DREAMS project has been an incredible journey. We have not only achieved significant milestones but have also laid the foundation for breakthroughs that will shape the future of neuromuscular disease treatment. Our collaborative approach, combining cutting-edge research with AI-driven innovation, is positioning us to make meaningful contributions to the field”.
Looking Ahead
The second year of the project is expected to be crucial. The aim is to transform initial successes into clinical solutions that improve patient outcomes. Key plans for the coming year include:
- Advancing Disease Modelling: A comprehensive collection of cells derived from iPS cell lines will be utilized to study common pathological features and explore autophagy defects related to these diseases.
- Drug Screening: Drug screening targeting autophagy will be initiated, along with the development of a second screening based on progress in disease modelling.
- Clinical Trial Preparation: Efforts to design patient-centered clinical trials will be intensified, with the first draft of trial protocols expected soon.
- AI-Driven Drug Target Discovery: Continued development of AI algorithms for the discovery of drug targets will be pursued, potentially yielding new indications and therapeutic candidates.
The second annual meeting of the DREAMS project not only highlighted the remarkable progress made thus far, but also set the stage for future advancements in the treatment of neuromuscular diseases. With a strong commitment to collaboration and innovation, DREAMS’s consortium is poised to translate these achievements into tangible solutions that will improve the lives of countless individuals affected by these conditions. As the journey continues, the focus remains on harnessing cutting-edge research with AI-driven innovation to unlock new therapeutic possibilities.
